Effect of a CCK-1R Agonist on Food Intake in Humans — GSK  

Bulimia Clinical Trial

Official title: Effect of a CCK-1R Agonist on Food Intake in Humans

Status Terminated

Clinical Trial Summary

The ultimate aim of this study is to test the hypothesis that the oral cholecystokinin (CCK) agonist GSKI181771X will reduce the size of a binge meal among individuals with Bulimia Nervosa. The study will be conducted in phases. First, an effective dose for reducing food intake, when normal subjects eat normally will be attained. Next, it will be determined whether intake at this dose is reduced in control subjects instructed to eat to capacity. If the dose is still effective compared to placebo, the same dose will be tested in patients with bulimia nervosa.

Clinical Trial Description

This study tests the hypothesis that an oral CCK antagonist GSKI181771X will reduce the size of a binge meal. It was intended to study the effects of increasing doses on antagonist on normal individuals to find an effective dose in a non-binge meal before moving to a binge meal. Once the effects of the antagonist on a binge meal were found, the compound would be used on patients with bulimia nervosa. However, the product expired and more was not available before the patients were tested. Data are presented for the normal participants who were instructed to eat normally, followed by a group that was instructed to binge eat. Comparisons were made between groups with different instructions and between binge and normal meals. ;

Related Conditions & MeSH terms

• Bulimia

• NCT number: NCT00600743
• Study type: Interventional
• Source: St. Luke's-Roosevelt Hospital Center
• Status: Terminated
• Phase: Phase 2
• Start date: January 2008
• Completion date: February 2009